Urology
Volume 72, Issue 6 , Pages 1212-1213, December 2008

Reply

  • Umberto Capitanio, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, Vita-Salute San Raffaele, Milan, Italy
    • ,
  • Sasha Ahyai, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Markus Graefen, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Andreas Erbersdobler, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Thorsten Schlomm, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Alexander Haese, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Thomas Steuber, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Hans Heinzer, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Hartwig Huland, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Claudio Jeldres, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Pierre I. Karakiewicz, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Shahrokh F. Shariat, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Paul Perrotte, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • François Péloquin, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Daniel Pharand, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Philippe Arjane, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0090-4295(08)00781-4

doi:10.1016/j.urology.2008.06.030

Refers to article:

  • Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer , 11 August 2008

    Umberto Capitanio, Sasha Ahyai, Markus Graefen, Claudio Jeldres, Shahrokh F. Shariat, Andreas Erbersdobler, Thorsten Schlomm, Alexander Haese, Thomas Steuber, Hans Heinzer, Paul Perrotte, François Péloquin, Daniel Pharand, Philippe Arjane, Hartwig Huland, Pierre I. Karakiewicz
    Urology December 2008 (Vol. 72, Issue 6, Pages 1208-1211)

  • Editorial Comment

    Jonathan Epstein
    Urology December 2008 (Vol. 72, Issue 6, Page 1212)

Urology
Volume 72, Issue 6 , Pages 1212-1213, December 2008

Article Tools